Bendamustine, Lenalidomide (Revlimid®) and Dexamethasone (BRd) as 2nd-line Therapy for Patients With Relapsed or Refractory Multiple Myeloma
Clinical trial NCT01701076 · COMPLETED
Trial details
- NCT number
- NCT01701076
- Sponsor
- Cantonal Hospital of St. Gallen
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2012-03-01
- Primary completion
- 2016-02-01
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.